Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Scher

Showing results (531-540 of 692) with videos related to

Pageof 70
Sort By:
The Lancet. Oncology|December 17, 2016
Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysisJulia Wilkerson, Kald Abdallah, Charles Hugh-Jones, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 21, 2008
Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancerDana Rathkopf, Michael A Carducci, Michael J Morris, et al.
The Journal of Clinical Investigation|January 6, 2006
Differential exoprotease activities confer tumor-specific serum peptidome patternsJosep Villanueva, David R Shaffer, John Philip, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2001
Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylaseL M Butler, Y Webb, D B Agus, et al.
The Journal of Clinical Investigation|January 26, 2013
β4 Integrin signaling induces expansion of prostate tumor progenitorsToshiaki Yoshioka, Javier Otero, Yu Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2017
Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and PrednisoneDana E Rathkopf, Emmanuel S Antonarakis, Neal D Shore, et al.
Journal of Oncology Practice|August 15, 2013
Prevalence of pain and analgesic use in men with metastatic prostate cancer using a patient-reported outcome measureKaren A Autio, Antonia V Bennett, Xiaoyu Jia, et al.
British Journal of Cancer|October 31, 2013
First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancerD Bianchini, A Omlin, C Pezaro, et al.
Urology|December 29, 2020
Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting SummaryMartin R Hofmann, Maha Hussain, Scott M Dehm, et al.
Vaccine|April 8, 2004
CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systemsPolly D Gregor, Jedd D Wolchok, Cristina R Ferrone, et al.
Pageof 70

Showing results (531-540 of 692) with videos related to

Sort By:
Pageof 70
The Lancet. Oncology|December 17, 2016
Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysisJulia Wilkerson, Kald Abdallah, Charles Hugh-Jones, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 21, 2008
Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancerDana Rathkopf, Michael A Carducci, Michael J Morris, et al.
The Journal of Clinical Investigation|January 6, 2006
Differential exoprotease activities confer tumor-specific serum peptidome patternsJosep Villanueva, David R Shaffer, John Philip, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2001
Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylaseL M Butler, Y Webb, D B Agus, et al.
The Journal of Clinical Investigation|January 26, 2013
β4 Integrin signaling induces expansion of prostate tumor progenitorsToshiaki Yoshioka, Javier Otero, Yu Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2017
Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and PrednisoneDana E Rathkopf, Emmanuel S Antonarakis, Neal D Shore, et al.
Journal of Oncology Practice|August 15, 2013
Prevalence of pain and analgesic use in men with metastatic prostate cancer using a patient-reported outcome measureKaren A Autio, Antonia V Bennett, Xiaoyu Jia, et al.
British Journal of Cancer|October 31, 2013
First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancerD Bianchini, A Omlin, C Pezaro, et al.
Urology|December 29, 2020
Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting SummaryMartin R Hofmann, Maha Hussain, Scott M Dehm, et al.
Vaccine|April 8, 2004
CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systemsPolly D Gregor, Jedd D Wolchok, Cristina R Ferrone, et al.
Pageof 70